Aptevo Therapeutics Inc
Veridion Score
Composite trend over time
Why is APVO moving today?
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for APVO.
APVO insider activity
Aptevo Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $20K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-12 | 2025-11-10 | Grant Grady III | Insider | buy | $1.49 | 13,513 | 13,514 | $20K | SEC Form 4 |
APVO contract awards, year to date.
Public federal awards linked to this ticker.
APVO lobbying filings, year to date.
Registered lobbying filings matched to Aptevo Therapeutics Inc.